

DR. JAMES MICHAEL NIALL DUFFY (Orcid ID : 0000-0001-6127-9859)

MR. DAN RICHARDS-DORAN (Orcid ID : 0000-0002-0527-0259)

BEN WJ MOL (Orcid ID : 0000-0001-8337-550X)

DR. PETER VON DADELSZEN (Orcid ID : 0000-0003-4136-3070)

Article type : Main research article

A core outcome set for pre-eclampsia research: An international consensus development study

James M. N. Duffy ^{1,2}, Alexandra E. Cairns ², Mr Dan Richards-Doran ², Janneke van 't Hooft ³, Chris Gale ⁴, Mark Brown ⁵, Lucy C Chappell ⁶, William A. Grobman ⁷, Ray Fitzpatrick ⁸, S. Ananth Karumanchi ⁹, A Khalil ¹⁰, D. Nuala Lucas ¹¹, Laura A. Magee ⁶, Ben W. Mol ¹², Michael Stark ¹³, Shakila Thangaratnam ¹⁴, Mathew J. Wilson ¹⁵, Peter von Dadelszen ⁶, Paula R. Williamson ¹⁶, Sue Ziebland ², Richard J. McManus ² and the International Collaboration to Harmonise Outcomes for Pre-eclampsia (iHOPE) (*listed at the end of the manuscript)

¹ Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.

² Institute for Women's Health, University College London, London, United Kingdom.

³ Department of Obstetrics and Gynaecology, Amsterdam UMC, Academic Medical Centre, Amsterdam, The Netherlands.

⁴ Academic Neonatal Medicine, Imperial College London, London, United Kingdom.

⁵ Department of Renal Medicine, St George Hospital and University of New South Wales, Kogarah, Australia.

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/1471-0528.16319](https://doi.org/10.1111/1471-0528.16319)

This article is protected by copyright. All rights reserved

⁶ Department of Women and Children's Health, School of Life Course Sciences, King's College London, London, United Kingdom.

⁷ Department of Obstetrics and Gynaecology, Feinberg School of Medicine, Northwestern University, Chicago, United States.

⁸ Health Services Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.

⁹ Cedars-Sinai Medical Centre, Los Angeles, California, United States.

¹⁰ Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute, St George's University of London, London, United Kingdom.

¹¹ London North West University Healthcare NHS Trust, Harrow, United Kingdom.

¹² Department of Obstetrics and Gynaecology, Monash University, Victoria, Australia.

¹³ Department of Obstetrics and Gynaecology, University of Adelaide, Adelaide, Australia.

¹⁴ Women's Health Research Unit, Barts and the London School of Medicine and Dentistry, London, United Kingdom.

¹⁵ School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom.

¹⁶ MRC North West Hub for Trials Methodology Research, Department of Biostatistics, University of Liverpool, Liverpool, United Kingdom.

Corresponding author

James M. N. Duffy

Nuffield Department of Primary Care Health Sciences, University of Oxford

Oxford, United Kingdom

+44 (0)7949 066806

james.duffy3@nhs.net

Running title

A core outcome set for pre-eclampsia

Objective To develop a core outcome set for pre-eclampsia.

Design Consensus development study.

Setting International.

Population Two hundred and eight one healthcare professionals, 41 researchers, and 110 patients, representing 56 countries, participated

Methods Modified Delphi method and Modified Nominal Group Technique.

Results A longlist of 116 potential core outcomes was developed, by combining the outcomes reported in 79 pre-eclampsia trials with those derived from thematic analysis of 30 in-depth interviews of women with lived experience of pre-eclampsia. Forty-seven consensus outcomes were identified from the Delphi process following which 14 maternal and eight offspring core outcomes were agreed at the consensus development meeting. Maternal core outcomes: death, eclampsia, stroke, cortical blindness, retinal detachment, pulmonary oedema, acute kidney injury, liver haematoma or rupture, abruption, postpartum haemorrhage, raised liver enzymes, low platelets, admission to intensive care required, and intubation and ventilation. Offspring core outcomes: stillbirth, gestational age at delivery, birth weight, small-for-gestational-age, neonatal mortality, seizures, admission to neonatal unit required, and respiratory support.

Conclusions The core outcome set for pre-eclampsia should underpin future randomised trials and systematic reviews. Such implementation should ensure future research holds the necessary reach and relevance to inform clinical practice, enhance women's care, and improve the outcomes of pregnant women and their babies.

Funding National Institute for Health Research, Barts Charity, and Elisabeth Garrett Anderson Hospital Charity Travelling Fellowship in Memory of Anne Boutwood, Royal College of Obstetricians and Gynaecologists.

Keywords Consensus development study, core outcome set, modified Delphi method, modified nominal group technique, outcome reporting bias, pre-eclampsia.

Tweetable abstract @HOPEoutcomes 281 healthcare professionals, 41 researchers, and 110 women have developed #preeclampsia @coreoutcomes

Introduction

When untreated, pre-eclampsia is life-threatening, and in low- and middle-income countries it is one of the leading causes of maternal mortality, severe maternal morbidity, and stillbirth. (1) The development of effective and safe treatments for pre-eclampsia is urgently needed. Potential treatments should be evaluated in randomised trials, and to ensure the greatest gains in reducing the current burden of mortality and severe morbidity associated with pre-eclampsia, research should be undertaken in all settings, including low- and middle-income countries. Several national and international organisations, including the World Health Organization, have prioritised over 50 unanswered research questions relating to the evaluation of potential treatments for pre-eclampsia. (2-4) However, complex issues including a failure to consider the perspectives of women with lived experience of pre-eclampsia when designing randomised trials, variations in outcome measures, and outcome reporting bias, could undermine the translation of future pre-eclampsia research into clinical practice.(5) Such research waste represents a substantial barrier to improving the care women and their babies receive.

A recent systematic review characterised outcome reporting across published pre-eclampsia trials.(6) This systematic evaluation illustrated the widespread variation in the reporting of maternal and offspring outcomes. Most pre-eclampsia trials did not report information on clinically important outcomes, including stroke, liver failure, and renal failure, and did not evaluate efficacy and safety in the participants' infants, particularly over the longer term.

The challenges of poor outcome selection, measurement, and reporting can be addressed by developing, disseminating, and implementing a core outcome set for future pre-eclampsia

research.(7) A core outcome set represents a minimum collection of outcomes and outcome measures, developed using robust consensus science methods, engaging diverse stakeholders including healthcare professionals, researchers, and patients.(7, 8) Core outcomes should be routinely used by researchers, collected in a standardised manner, and reported consistently in the final publication allowing comparability between individual randomised trials and efficient meta-analysis.(7, 9)

The objective of this study was to develop a clinically relevant core data set to standardise outcome selection, collection, and reporting across future randomised trials and systematic reviews evaluating potential treatments for pre-eclampsia.

Methods

The study was prospectively registered with the Core Outcome Measures in Effectiveness Trials (COMET) Initiative, registration number 588. A protocol with explicitly defined objectives, formal consensus development methods, criteria for participant identification and selection, and statistical methods has been published.(10)

An international steering group, including health care professionals, researchers, and women with lived experience of pre-eclampsia, was established to provide a perspective to inform key methodological decisions. The core outcome set was developed in a three-stage process using consensus science methods advocated by the COMET initiative.(7)

There is no international consensus regarding the diagnostic criteria for pre-eclampsia. The study did not seek to reach consensus regarding the definition of pre-eclampsia and adopted the International Society for the Study of Hypertension in Pregnancy's pre-eclampsia definition, which is defined as gestational hypertension presenting with new-onset proteinuria, other maternal organ dysfunction, and / or uteroplacental dysfunction.(11) This study is complementary to the work of the Global Pregnancy Collaboration and the International Society for the Study of Hypertension in Pregnancy who are engaged with the standardisation of other aspects of study design, the development of a standardised database for perinatal research studies, and the development of clinical practice guidelines.

Potential core outcomes were identified by extracting outcomes reported in published pre-eclampsia trials and undertaking a thematic analysis of in-depth interviews with women with lived

experience of pre-eclampsia. Both studies have been published.(6, 12) A comprehensive inventory of outcomes and plain language descriptions was developed in consultation with the study's steering group. This inventory was entered into a modified Delphi method which was delivered through sequential online surveys using Delphi survey software (DelphiManager, University of Liverpool, Liverpool, United Kingdom).

Health care professionals, researchers, and women with lived experience of pre-eclampsia were invited to participate. Healthcare professionals were recruited through the Core Outcomes in Women's and Newborn Health (CROWN) initiative, Global Obstetrics Network, and the International Society for the Study of Hypertension in Pregnancy. Researchers were recruited through participation in ongoing pre-eclampsia research studies including: (1) community blood pressure monitoring in rural Africa and Asia;(13) (2) detection of underlying pre-eclampsia study, development and validation of a prediction model for risk of complications in early-onset pre-eclampsia study;(14) (3) international prediction of pre-eclampsia individual patient data collaborative network; and (4) pre-eclampsia: eclampsia monitoring, prevention, and treatment initiative.(15) Women with lived experience of pre-eclampsia were recruited through patient organisations including Action on Pre-eclampsia; Count the Kicks; Group B Strep Support; and Tommy's. The Delphi method does not depend on statistical power and between ten and 15 participants has been demonstrated to yield sufficient results.(16-18) The study aimed to recruit at least 18 participants for each stakeholder group but planned to maximise the number to increase generalisability, anticipating an overall attrition rate of 20%.

The round one survey was piloted by the study's steering group before use. Feedback was specifically sought regarding the survey instructions, ease of completion, the appropriateness of terminology, and time taken to complete the survey. The survey was adjusted in response to feedback.

Before entering the round one survey, participants received an explanatory video abstract, a plain language summary, and survey instructions, provided demographic details, and made an explicit commitment to complete all three rounds. Following registration, a unique identifier was generated and allocated to each participant, to ensure future responses were both linked and anonymised. In round one, participants scored individual outcomes on a nine-point Likert scale.(19) Participants were able to select an 'unable to score' category if they did not feel they had sufficient expertise or experience to score an individual outcome. Before completing the survey, participants were able to suggest additional outcomes. After the round one survey had

closed, the scores for each outcome were aggregated across individual stakeholder groups. The percentage of participants scoring each outcome at every possible response from one to nine was calculated by the Delphi survey software and tabulated for individual stakeholder groups. Suggested additional outcomes were reviewed by the steering group and unique outcomes were entered into round two.

In round two, participants received their own scores and individual stakeholder group feedback for each round one outcome. Participants were asked to reflect on their own scores and on the scores of other participants, before rescoreing each outcome. Before completing the survey, participants were able to score additional outcomes suggested by participants in the round one survey. After the round two survey had closed, the percentage of participants scoring each outcome at every possible response from one to nine was calculated and tabulated for individual stakeholder groups.

In round three, participants received their own scores and individual stakeholder group feedback for each round two outcome. Participants were asked to reflect on their own scores and on the scores of other participants before rescoreing each outcome. After the round three survey had closed, it was agreed prior to reviewed the results that a consensus definition would be identified when over 70% of participants in each stakeholder group scored the outcome 'critical for decision making' (score seven to nine) and less than 15% of participants in each stakeholder group score the outcome 'of limited importance for decision making' (score one to three).(7) Participants who withdrew from the Delphi survey were requested to complete an anonymous online questionnaire providing free text comments outlining their reason(s) for withdrawing. These responses were coded and summarised.

With regard to the other consensus method utilised in the study, the modified nominal group technique was delivered through a half-day consensus development meeting.(18) Healthcare professionals, researchers, and women with lived experience of pre-eclampsia, resident in the United Kingdom, and who had completed all three rounds of the Delphi survey were invited to participate in a consensus development meeting. Anyone who responded favorably was extended an invitation to attend the consensus development meeting. The modified nominal group technique does not depend on statistical power and there is no robust method for calculating the required number of participants. The study aimed to recruit between ten and 15 participants as this number has assured validity in other settings.(18, 20)

Before the meeting, participants provided demographic details and made an explicit commitment to participate actively. All consensus outcomes were entered into the process. Participants were able to enter other outcomes which had not reached the consensus threshold, upon request. Following an initial discussion, outcomes were divided into three provisional categories: (1) outcomes to be considered for inclusion in the final core outcome set; (2) outcomes where no consensus existed; and (3) outcomes which should not be considered for inclusion in the final core outcome set. Participants were invited to discuss the ordering of the outcomes within each category, considering contextual information, including the relative importance of individual outcomes, feasibility to collect the outcome data, and the availability of suitable definitions and measurement instruments. They were encouraged to reformulate outcomes to improve clarity or comprehension. The discussion focused upon ranking the outcomes being considered for inclusion in the final core outcome set and the outcomes where no consensus existed. During the discussion, the outcomes could be moved between the categories. Finally, the core outcome set was agreed.

Descriptive statistics were used to describe participant demographics. Medians (\bar{x}), interquartile ranges (IQR), and scoring distributions were calculated across individual stakeholder groups (healthcare professionals, researchers, and patients) and pooled across individual outcomes. The skewness of each scoring distribution was calculated using Pearson's coefficient of skewness (Sk_2). All analyses were performed using GraphPad Prism (GraphPad software, United States).

The study was funded by the National Institute for Health Research, Barts Charity, and Elisabeth Garrett Anderson Hospital Charity Travelling Fellowship in Memory of Anne Boutwood, Royal College of Obstetricians and Gynaecologists.

Results

Seventy-nine pre-eclampsia trials reported 106 different outcomes and thematic analysis of 30 in-depth interviews with women with lived experience of pre-eclampsia identified 71 outcomes (Figure 1).^(6, 12) Combining these resulted in 116 unique outcomes which were entered into the Delphi survey.⁽²¹⁾

The Delphi survey was started by 281 healthcare professionals, 41 researchers, and 110 women with lived experience of pre-eclampsia, representing 31 high-income countries and 25 low- and middle-income countries (Table 1). Over the three Delphi survey rounds, 159 participants (37%)

withdrew, including 100 healthcare professionals (35%), 11 researchers (27%) and 48 patients (44%). The majority of participants who withdrew from the survey provided an explanation (Table S1). In response to the outcomes suggested by participants, the steering group recommended the reformulation of 11 outcomes to improve clarity and added 20 new outcomes to round two (Figure S1). Therefore, 136 outcomes were subsequently entered into rounds two and three. In round three results, 47 outcomes reached the consensus threshold (Appendix S1).

The consensus development meeting included 11 healthcare professionals, two researchers, and four women with lived experience of pre-eclampsia. Nine participants (56%) had lived, worked, or conducted research in low- or middle-income countries. Forty-seven consensus outcomes were considered using the modified nominal group technique. Participants recommended the reformulation of nine consensus outcomes and entered an additional four no consensus outcomes into the process.

Participants prioritised 22 outcomes, comprising 14 maternal and eight offspring outcomes, for inclusion in the core outcome set for pre-eclampsia (Table 2). Outcomes represented maternal and infant mortality and severe morbidity. These included maternal mortality, stroke, pulmonary oedema, acute kidney injury, placental abruption, and postpartum haemorrhage. Outcomes demonstrating the impact of pre-eclampsia on the fetus and neonate included stillbirth and neonatal mortality, gestational age at delivery and birth weight, and neonatal seizures. Finally, outcomes representing the resource utilisation resulting from the management of severe maternal and neonatal morbidity included the requirement for maternal admission to intensive care, the requirement for neonatal unit admission, and respiratory support.

Discussion

Main findings

Using robust consensus science methods, healthcare professionals, researchers, and women with experience of pre-eclampsia have developed a core outcome set to standardise outcome selection, collection, and reporting across future pre-eclampsia trials and systematic reviews.

Strengths and limitations

This study has met the recently published standards for core outcome set development, developed by an international group of experienced core outcome set developers, methodologists, and potential core outcome set end users.(22) By meeting these recommendations, this study has objectively demonstrated its methodological quality. When considering core outcome set development, a high number of diverse participants is desirable to secure the generalisability of the results and increase its credibility with other researchers. With over 400 participants from 56 countries, the global participation achieved in this study should secure the relevance of the results across an international context. The core outcome set for pre-eclampsia is perceived as an exemplar of core outcome set development and the study's approach has been adopted by many other core outcome set development studies.(23-26)

This consensus study is not without limitations. There is considerable uncertainty regarding core outcome set development methods.(27) The optimal approaches to selecting participants, structuring interaction embedded in different consensus methods, including modified Delphi method, modified Nominal Group Technique, and consensus development conference, and methods of synthesising individual judgements. Further methodological research is required to inform future core outcome set development.

When considering the Delphi survey, there was a higher response from participants who identified as white (83%), living in Europe (55%), and living in high-income countries (82%). To participate in the Delphi survey, English proficiency, a computer, and internet access were required. Limitations in the representativeness of the sample could have impacted upon the outcomes prioritised, however, given the wide range of outcomes from the previous worldwide literature that fed into the process, this should not have been a major issue.

The study's attrition rate was 37%, which is comparable to other core outcome set development studies in women's and newborn health.(8) This did vary between stakeholder groups with more patients (44%) dropping out than other groups, such as healthcare professionals (35%) and researchers (27%). It may have been possible to reduce attrition, particularly within the patient stakeholder group, by reducing the length of the survey. However, attrition needed to be balanced with the requirement to enter a comprehensive longlist of potential core outcomes into the Delphi survey and for participants to be able to reflect on and rescore individual outcomes in relation to each other.

Although the notion of achieving consensus is fundamental to core outcome set development, the definition of what constitutes consensus is less clear. The pre-specified consensus definition applied within the Delphi survey could be considered as being too accommodating, as it resulted in the identification of 47 initial consensus outcomes. Further methodological research is required to develop an appropriate consensus definition which could accommodate the skewed scoring distribution of the respondents.(28)

Interpretation

Most trials evaluating potential treatments for pre-eclampsia have neglected to report many of the outcomes included in the core outcome set.(6, 29) For example, only a third of trials have reported eclampsia, less than a tenth of trials have reported stroke, and only three trials have reported pulmonary oedema.(6) Selective reporting of outcomes, based on statistical significance, could be contributing to these omissions.(30) Systematic implementation of the core outcome set for pre-eclampsia should ensure future pre-eclampsia research reports outcomes that matter to healthcare professionals, researchers, and women with pre-eclampsia, and help to limit selective reporting of results based upon statistical significance. Such an approach could be replicated in other areas of women's and newborn health, including endometriosis, twin-twin transfusion syndrome, and neonatal care, to tackle the variation in outcome reporting and suspected outcome reporting bias.(31-33)

It is considered good practice for researchers planning randomised trials to implement the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) statement which outlines the scientific, ethical, and administrative elements that should be addressed in a clinical trial protocol.(34) This statement specifically recommends the use of core outcome sets where they exist. In addition, the importance of implementing core outcome sets is recognised by the funders of health research.

The CROWN initiative, supported by over 80 specialty journals, have resolved to implement this core outcome set.(8) Participating journals will require researchers to report core outcomes within manuscripts and offer conclusions based on these outcomes. Where core outcome sets have not been collected, the researchers will be asked to report this deficiency and its implications for their findings.(9)

The Cochrane Pregnancy and Childbirth Group have committed to implementing the core outcome set for pre-eclampsia when new and updated reviews are being prepared. Uptake of the

core outcome set should facilitate the possibility of more sophisticated methods of evidence synthesis, including individual patient data (IPD) meta-analysis and network meta-analysis.

The core outcome set has been developed specifically for comparative effectiveness research. The use of this core outcome set in other types of research is highly desirable. There is currently a research priority setting partnership developing research priorities for hypertension in pregnancy.⁽³⁵⁾ This work should be considered complementary to a wider agenda of reducing research waste across hypertension in pregnancy research. Such agendas have been proposed in areas relevant to women's health, including twin and multiple pregnancy research with research priority setting and core outcome set development as important components.^(36, 37)

Blood pressure and severe hypertension were not identified as core outcomes. In adult non-pregnant populations, blood pressure is a valid surrogate outcome for heart disease, stroke, and mortality.⁽³⁸⁻⁴⁰⁾ In the context of pre-eclampsia research, maternal blood pressure has been commonly selected as a surrogate outcome, which represents a single pathway that operates within a complex multifactorial disease, characterised by vasoconstriction, coagulation, and intravascular fluid redistribution, resulting in widespread microthrombi formation and necrosis within maternal end-organs.^(6, 41, 42) Reliable conclusions around the impact of pre-eclampsia interventions cannot necessarily be informed by reductions in maternal blood pressure as the consequences of blood pressure changes upon a diverse range of clinically meaningful outcomes, including maternal mortality, pulmonary edema, and renal failure, may be unclear. Developing a core outcome set for pre-eclampsia represents an opportunity to deliver a paradigm shift by measuring treatment effectiveness as a clinical rather than a biological response. Researchers should continue to report blood pressure as a descriptive outcome.

Core outcomes require standardised outcome measures. Without a standardised approach, researchers would be able to choose from a variety of different outcome measures for individual core outcomes. Such variation can make it difficult to synthesise the results of individual trials within secondary research.⁽³⁶⁾ The collaboration has standardised definitions using formal consensus development methods to secure additional harmony across future pre-eclampsia trials and ensure secondary research can be undertaken prospectively, efficiently, and harmoniously.⁽⁴³⁾ It is intended these consensus outcome measures will be used for core outcomes included in other core outcome sets relevant to women's and newborn health.⁽⁴⁴⁻⁵⁰⁾

Conclusion

This core outcome set for pre-eclampsia should now underpin all future randomised trials and systematic reviews evaluating potential treatments for pre-eclampsia. Such rationalisation should ensure that future research addresses outcomes agreed as important in a consistent manner, facilitate meta-analysis, enhance patient care, and ultimately improve the outcomes of pregnant women and their babies.

International Collaboration to Harmonise Outcomes for Pre-eclampsia (iHOPE)

Dr Edgardo J. Abalos, Centro Rosarino de Estudios Perinatales, Argentina; Christine C. D. Adamson, Chelsea and Westminster Hospital NHS Foundation Trust, United Kingdom; Dr Adebayo A. Akadri, Babcock University, Nigeria; Professor Zekeriya Akturk, Ailem Academic Counselling, Turkey; Professor Karel Allegaert, KU Leuven, Belgium; Dr Edith Angel-Müller, Universidad Nacional de Colombia, Colombia; Jessica Antretter, Northwell Health, United States; Dr Helen F. Ashdown, University of Oxford, United Kingdom; Professor Francois Audibert, Université de Montréal, Canada; Dr Nathalie Auger, University of Montreal Hospital Centre, Canada; Professor Canan Aygun, Ondokuz Mayıs University, Turkey; Dr Inas Babic, Prince Sultan Military Medical City, Saudi Arabia; Professor Rashmi Bagga, Postgraduate Institute of Medical Education and Research, Chandigarh, India; Judith M. Baker, South Africa; Dr Pradipta Bhakta, University Hospital Limerick, Ireland; Professor Vineet Bhandari, Drexel University, United States; Dr Sohinee Bhattacharya, University of Aberdeen, United Kingdom; Dr Marco H. Blanker, University of Groningen, The Netherlands; Professor Frank H. Bloomfield, University of Auckland, New Zealand; Dr Anna Bof, Australia; Siobhan M. Brennan, Ireland; Dr Kim Broekhuijsen, Haaglanden Medisch Centrum, The Netherlands; Professor Emeritus Fiona Broughton Pipkin, Nottingham University Medical School, United Kingdom; Dr Joyce L. Browne, Utrecht University, The Netherlands; Dr Roger M. Browning, King Edward Memorial Hospital for Women, Australia; Jameson W. Bull, United States; Dr Amina Butt, Saudi Arabia; Dena Button, United States; Dr Jeremy P. Campbell, Imperial College Healthcare NHS Trust, United Kingdom; Dr Doris M. Campbell, University of Aberdeen, United Kingdom; Professor Lionel Carbillon, Jean-Verdier Hospital, France; Sarah Carthy, United Kingdom; Dr Emma Casely, United Kingdom; Dr James A. Cave, Downland Practice, United Kingdom; Professor Jose G. Cecatti, University of Campinas, Brazil; Dr Mónica E. Chamillard, Centro Rosarino de Estudios Perinatales, Argentina; Professor Dominique Chassard, Université Lyon, France; Dr Nancy C. Checheir, University of North Carolina School of Medicine, United States; Professor Vasilii S. Chulkov, South Ural State Medical University, Russia; Dr Catherine A. Cluver, Stellenbosch University, South Africa; Carole F. Crawford, University of Oxford, United Kingdom; Mandy C. Daly, Irish Neonatal Health Alliance, Ireland; Professor Dorota A. Darmochwal-Kolarz, University

of Rzeszow, Poland; Ruth E. Davies, United Kingdom; Professor Mark W. Davies, Royal Brisbane and Women's Hospital, Australia; Dr James S. Dawson, Nottingham University Hospitals NHS Trust, United Kingdom; Nichola Dobson, United Kingdom; Claire N. Dodd, University Hospitals of Leicester, United Kingdom; Dr Fiona Donald, North Bristol NHS Trust, United Kingdom; Emeritus Professor Lelia Duley, University of Nottingham, United Kingdom; Jorie Epstein-Mares, United States; Professor Offer Erez, Soroka University Medical Center Ben Gurion University of the Negev, Israel; Dr Emma Evans, St George's University Hospitals NHS Foundation Trust, United Kingdom; Dr Richard N. Farlie, Hospitalsenhed Midt, Denmark; Amy V. Ferris, United Kingdom; Elizabeth M. Frankland, United Kingdom; Dr Dilys J. Freeman, University of Glasgow, United Kingdom; Dr Shalini Gainer, Postgraduate Institute of Medical Education and Research, India; Dr Wessel Ganzevoort, Amsterdam Universitair Medische Centra, The Netherlands; Dr Oghenekome A. Gbinigie, United Kingdom; Dr Sanjib K. Ghosh, All India Institute of Medical Sciences Patna, India; Dr Margaret Glogowska, University of Oxford, United Kingdom; Andrea Goodlife, University Hospitals of Leicester, United Kingdom; Dr Katie L. Gough, Luton and Dunstable University Hospital, United Kingdom; Jessica R. Green, United Kingdom; Professor Fouzia Gul, Khyber Medical University Institution of Medical Sciences, Pakistan; Lorraine Haggerty, Midwife Mid Essex Hospitals NHS Trust, United Kingdom; Professor David R. Hall, Stellenbosch University, South Africa; Professor Mikko Hallman, University of Oulu, Finland; Leigh M. Hamilton, New Zealand; Dr Sarah J. Hammond, St George's University Hospitals NHS Foundation Trust, United Kingdom; Professor Sloban D. Harlow, University of Michigan, United States; Dr Karen E. Hays CNM, Bastyr University, United States; Stacey C. Hickey, New Zealand; Mary Higgins, Irish Nurses and Midwives Organisation, Ireland; Dr Lisa Hinton, University of Oxford, United Kingdom; Associate Professor Sebastian R. Hobson, University of Toronto, Canada; Dr Matthew J. Hogg, Barts Health NHS Trust, United Kingdom; Heidi J. Hollands, University Hospitals Plymouth NHS Trust, United Kingdom; Professor Caroline S. E. Homer, Burnet Institute, Australia; Dr Zahra Hoodbhoy, Aga Khan University, Pakistan; Dr Paul Howell, Barts Health NHS Trust, United Kingdom; Professor Berthold Huppertz, Medical University of Graz, Austria; Dr Shahid Husain, Homerton University Hospital NHS Foundation Trust, United Kingdom; Dr Susan D. Jacoby, Mount Royal University, Canada; Professor Evelyne Jacqz-Aigrain, Université de Paris, France; Dr Gareth Jenkins, Royal Surrey County Hospital, United Kingdom; Dr David Jewel, United Kingdom; Dr Mark J. Johnson, University Hospital Southampton NHS Foundation Trust, United Kingdom; Dr Carolyn L. Johnston, St George's University Hospitals NHS Foundation Trust, United Kingdom; Paige M. Jones, United Kingdom; Professor Ira Kantrowitz-Gordon, University of Washington School of Nursing, United States; Dr Rehan-Uddin Khan, Barts Health NHS Trust, United Kingdom; Lisa J. Kirby, United Kingdom; Catherine

Kirk, United Kingdom; Professor Marian Knight, University of Oxford, United Kingdom; Mary T. Korey, United States; Dr Geraint J. Lee, Evelina London Children's Hospital Neonatal Unit, United Kingdom; Associate Professor Vincent W. Lee, University of Sydney, Australia; Dr Louis S. Levene, University of Leicester, United Kingdom; Dr Ambrogio P. Londero, Academic Hospital of Udine, Italy; Associate Professor Karin M. Lust, Royal Brisbane and Women's Hospital, Australia; Dr Vanessa MacKenzie, NHS Borders, United Kingdom; Dr Line Malha, Weill Cornell Medical College, United States; Dr Massimo Mattone, Italy; Dr David E. McCartney, United Kingdom; Professor Alison McFadden, University of Dundee, United Kingdom; Professor Brian H. McKinstry, University of Edinburgh, United Kingdom; Associate Professor Philippa F. Middleton, South Australian Health and Medical Research Institute, Australia; Dr Hiten D. Mistry, University of Nottingham, United Kingdom; Dr Caroline A. Mitchell, University of Sheffield, United Kingdom; Joanne C. Mockler, Monash University and Monash Health, Australia; Sally-Ann Molsher, United Lincolnshire Hospitals NHS Trust, United Kingdom; Elizabeth S. Monast, United States; Professor Emeritus Jagidesa Moodley, University of Kwa Zulu-Natal, South Africa; Dr Rob Mooij, Beatrix Hospital, The Netherlands; Emma L. Moore, United Kingdom; Dr Linda Morgan, University of Nottingham, United Kingdom; Dr Angela Moulson, United Kingdom; Dr Faraz Mughal, Keele University, United Kingdom; Dr Shuchita R. Mundle, Government Medical College, Nagpur, India; Dr Miguel Angel Munoz, Institut Catala de la Salut. IdiapJgol, Spain; Professor Elizabeth Murray, University College London, United Kingdom; Dr Chie Nagata, National Center for Child Health and Development, Japan; Dr Abhijit S. Nair, Basavataarakam Indo-American Cancer Hospital and Research Institute, India; Professor Annette Nakimuli, Uganda; Dr Gita Nath, Axon Anaesthesia Associates, India; Rachel S. Newport, Pennine Acute Hospitals NHS Trust, United Kingdom; Professor Pippa Oakeshott, St George's, University of London, United Kingdom; Dr Maria R. Ochoa-Ferraro, Norfolk and Norwich University Hospital, United Kingdom; Professor Hein Odendaal, Stellenbosch University, South Africa; Professor Akihide Ohkuchi, Jichi Medical University School of Medicine, Japan; Professor Leandro Oliveira, São Paulo State University, Brazil; Dr Eduardo Ortiz-Panozo, National Institute of Public Health, Mexico; Dr Martijn A. Oudijk, Amsterdam Universitair Medische Centra, The Netherlands; Dr Seyhan E. Oygucu, University of Kyrenia, Turkey; Emeritus Professor Michael J. Paech, King Edward Memorial Hospital, Australia; Dr Rebecca C. Painter, Amsterdam University Centres, The Netherlands; Claire L. Parry, United Kingdom; Dr Beth A. Payne, University of British Columbia, Canada; Emma L. Pearson, United Kingdom; Professor Vorapong Phupong, Chulalongkorn University, Thailand; Naomi Pickett, United Kingdom; Katie A. Pickles, United Kingdom; Louise K. Plumb, United Kingdom; Dr Federico Prefumo, University of Brescia, Italy; Professor Roanne Preston, University Of British Columbia, Canada; Dr Joel G. Ray, University of Toronto, Canada; Dr Juliet Rayment, United

Kingdom; Lynsey V. Regan, United Kingdom; Dr Evelyne Rey, University of Montreal, Canada; Dr Emily J. Robson, United Kingdom; Antonia N. Rubin, United Kingdom; Professor Jorge A. Rubio-Romero, Universidad Nacional de Colombia, Colombia; Dr Kristiina Rull, Women's Clinic of Tartu University Hospital, Estonia; Professor Nelson Sass, Universidade Federal de São Paulo, Brazil; Professor Nadine Sauvé, Université de Sherbrooke, Canada; Nicola A. Savory, University Hospital of Wales, United Kingdom; Professor James R. Scott, University of Iowa, United States; Dr Sarah E. Seaton, University of Leicester, United Kingdom; Paul T. Seed, King's College London, United Kingdom; Dr Judy M. Shakespeare, United Kingdom; Dr Antonia W. Shand, University of Sydney, Australia; Dr Sanjay Sharma, Westmead Hospital, Australia; Dr Tammy Y. Shaw, Canada; Dr Kate L. Smedley, United Kingdom; Dr Drew Smith, Princess Royal Maternity, United Kingdom; Ashley Smith Conk, United States; Donna Soward, Australia; Professor Holger Stepan, Leipzig University, Germany; Dr Konstantinos Stroumpoulis, Centre Hospitalier Public du Cotentin, France; Dr Anoop Surendran, Lewisham and Greenwich NHS Trust, United Kingdom; Professor Satoru Takeda, Juntendo University Faculty of Medicine, Japan; Dr Lawrence Tan, Western Sydney University, Australia; Becky S. Theriot, United States; Hayley F. Thomas, Netherlands; Karen Thompson, Australia; Dr Peter I. Thompson, National Institute of Health Research, United Kingdom; Professor Matthew J. Thompson, University of Washington, United States; Laura Toms, United Kingdom; Kate L. H. T. Torney, United Kingdom; Dr Julian S. Treadwell, University of Oxford, United Kingdom; Dr Katherine L. Tucker, University of Oxford, United Kingdom; Dr Mark A. Turrentine, Baylor College of Medicine, United States; Dr Oliver Van Hecke, University of Oxford, United Kingdom; Dr Miriam F. Van Oostwaard, Capelle aan den IJssel, The Netherlands; Dr Daniela N. Vasquez, Sanatorio Anchorena, Argentina; Dr David J. A. Vaughan, London North West University Healthcare NHS Trust, United Kingdom; Dr Angela VInturache, Oxford University Hospitals NHS Foundation Trust, United Kingdom; Professor James Walker, University of Leeds, United Kingdom; Dr Stephen P. Wardle, Nottingham University Hospitals NHS Trust, United Kingdom; Professor Tayyiba Wasim, Institute of Medical Sciences, Lahore, Pakistan; Dr Jonathan H. Waters, UPMC Magee Womens Hospital, United States; Dr Clare L. Whitehead, University of Toronto, Canada; Dr Alexander Wolfson, Penn Medicine Princeton Health, United States; Professor Seonae Yeo, University of North Carolina at Chapel Hill, United States; and Dr Arnold G. Zermansky, University of Leeds, United Kingdom.

Acknowledgments

This work reports independent research arising from a doctoral fellowship (DRF-2014-07-051) supported by the National Institute for Health Research, Barts Charity, and Elisabeth Garrett Anderson Hospital Charity Travelling Fellowship in Memory of Anne Boutwood. Dr Chris Gale

was supported by a Medical Research Council Clinician Scientist Fellowship. Prof Richard McManus was supported by a National Institute for Health Research Professorship (NIHR-RP-R2-12-015) and the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care Oxford. Prof Richard McManus, Prof. Paula Williamson, and Prof Sue Ziebland are supported by National Institute for Health Research Senior Investigator awards. Prof Ben Mol is supported by a National Health and Medical Research Council Investigator Grant. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research, or the Department of Health.

We would like to thank the Delphi survey and consensus development meeting participants. We would like to thank the Radcliffe Women's Health Patient Participation group, Action on Pre-eclampsia, and our patient and public representatives who assisted with study design, data interpretation, and planned dissemination. We would like to thank colleagues at the Nuffield Department of Primary Care Health Sciences, University of Oxford including Jacqui Belcher, Carla Betts, Lucy Curtin, Dawn Evans, Caroline Jordan, Sarah King, Sam Monaghan, Nicola Small, and Clare Wickings for administrative, technical, or material support. We would like to thank Prof. Marian Knight, Nuffield Department of Population Health, University of Oxford, for providing subject-specific expertise. We would like to thank colleagues at the Women's Health Research Unit, Queen Mary, University of London, including Khalid Khan, Rehan Khan, and Tracy Holtham for administrative, technical support, or subject-specific expertise. We would like to thank David J. Mills for administrative and logistical support.

Conflicts of interest

Dr Gale has received expenses to attend an educational conference from Chiesi Pharmaceuticals and his institution has received research funding from Chiesi Pharmaceuticals. Prof Karumanchi reports receiving research funding from Siemens, serving as a consultant to Roche and Thermofisher Scientific, having a financial interest in Aggamin Pharmaceuticals, and holding multiple patents. Prof Khalil reports being the inventor of the Hampton system. Prof Mol reports consultancy fees from Guerbet, iGenomix, Merck KGaA, and ObsEva. Prof McManus reports research support from Omron. The remaining authors declare no competing interests. Completed disclosure of interest forms are available to view online as supporting information.

Author contributions

Study concept and design: JMD, PRW, SZ, and RJM. Acquisition of data: JMD, AEC, DRD, JVH, CG, MB, LCC, WAG, RF, SAK, AK, DNL, LM, BWM, MS, ST, MJW, PVD, PRW, SZ, RJM.

Analysis and interpretation of data: JMD, AEC, DRD, JVH, CG, MB, LCC, WAG, RF, SAK, AK, DNL, LM, BWM, MS, ST, MJW, PVD, PRW, SZ, RJM. Drafting of the manuscript: JMD, SZ, and RJM. Critical revision of the manuscript for important intellectual content: JMD, AEC, DRD, JVH, CG, MB, LCC, WAG, RF, SAK, AK, DNL, LM, BWM, MS, ST, MJW, PVD, PRW, SZ, RJM. Obtaining funding: JMD, PRW, SZ, and RJM. Study supervision: JMD, PRW, SZ, and RJM.

Sources of funding

This study was funded by the Barts Charity, Elisabeth Garrett Anderson Hospital Charity, and National Institute for Health Research. The funders have no role in the design and conduct of the study, the collection, management, analysis, or interpretation of data, or manuscript preparation.

Ethical approval

Ethical approval was received from the National Research Ethics Service (reference number: 12/SC/0495; 1st July 2015).

References

1. Duley L. The global impact of preeclampsia and eclampsia. *Seminars in Perinatology*. 2009;33(3):130-7.
2. Task Force on Hypertension in Pregnancy. *Hypertension in pregnancy*. Washington, United States: American College of Obstetricians and Gynecologists; 2013.
3. National Collaborating Centre for Women's and Children's Health. *Hypertension in pregnancy: The management of hypertensive disorders during pregnancy*. NICE Clinical Guidelines, No. 107. London, United Kingdom: Royal College of Obstetricians and Gynaecologists Press; 2010.
4. World Health Organization Department of Reproductive Health and Research. *WHO recommendations for prevention and treatment of preeclampsia and eclampsia*. Geneva, Switzerland: World Health Organization; 2011.
5. Duffy JMN, Ziebland S, von Dadelszen P, McManus RJ. Tackling poorly selected, collected, and reported outcomes in obstetrics and gynecology research. *American Journal of Obstetrics & Gynecology*. 2019;220(1):71.e1-.e4.
6. Duffy JMN, Hirsch M, Kawsar A, Gale C, Pealing L, Plana MN, et al. Outcome reporting across randomised controlled trials evaluating therapeutic interventions for pre-eclampsia. *BJOG: An International Journal of Obstetrics and Gynaecology*. 2017;124(12):1829-39.

7. Williamson PR, Altman DG, Bagley H, Barnes KL, Blazeby JM, Brookes ST, et al. The COMET Handbook: Version 1.0. *Trials*. 2017;18(S3):280.
8. Duffy JMN, Rolph R, Gale C, Hirsch M, Khan KS, Ziebland S, et al. Core outcome sets in women's and newborn health: A systematic review. *BJOG: An International Journal of Obstetrics and Gynaecology*. 2017;124(10):1481-9.
9. Khan KS, Romero R. The CROWN Initiative: journal editors invite researchers to develop core outcomes in women's health. *American Journal of Obstetrics & Gynecology*. 2014;211(6):575-6.
10. Duffy JMN, van 't Hooft J, Gale C, Brown M, Grobman W, Fitzpatrick R, et al. A protocol for developing, disseminating, and implementing a core outcome set for pre-eclampsia. *Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health*. 2016;6(4):274-8.
11. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. Hypertensive Disorders of Pregnancy. *Hypertension*. 2018;72(1):24-43.
12. Duffy JMN, Thompson T, Hinton L, Salinas M, McManus RJ, Ziebland S. What outcomes should researchers select, collect, and report in pre-eclampsia research? A qualitative study exploring the views of women with lived experience of pre-eclampsia. *BJOG: An International Journal of Obstetrics and Gynaecology*. 2019;126(5):637-46.
13. de Greeff A, Nathan H, Stafford N, Liu B, Shennan AH. Development of an accurate oscillometric blood pressure device for low resource settings. *Blood Pressure Monitoring*. 2008;13(6):342-8.
14. Allotey J, Snell KIE, Chan C, Hooper R, Dodds J, Rogozinska E, et al. External validation, update and development of prediction models for pre-eclampsia using an Individual Participant Data (IPD) meta-analysis: The International Prediction of Pregnancy Complication Network (IPPIC pre-eclampsia) protocol. *Diagnostic and Prognostic Research*. 2017;1(1):16.
15. von Dadelszen P, Sawchuck D, Hofmeyr JG, Magee LA, Bracken H, Mathai M, et al. PRE-EMPT (PRE-eclampsia-Eclampsia Monitoring, Prevention and Treatment): A low and middle income country initiative to reduce the global burden of maternal, fetal and infant death and disease related to pre-eclampsia. *Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health*. 2013;3(4):199-202.
16. Giannarou L, Zervas E. Using Delphi technique to build consensus in practice. *International Journal of Business Science and Applied Management*. 2014;9(2):65-82.
17. Skulmoski GJ, Hartman FT, Krahn J. The Delphi method for graduate research. *Journal of Information Technology Education: Research*. 2007;6:1-21.

18. Murphy M, Sanderson C, Black N, Askham J, Lamping D, Marteau T, et al. Consensus development methods, and their use in clinical guideline development. *Health Technology Assessment*. 1998;2(3):1-88.
19. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. *Journal of Clinical Epidemiology*. 2011;64(4):395-400.
20. Gallagher M, Hares TIM, Spencer J, Bradshaw C, Webb IAN. The nominal group technique: A research tool for general practice? *Family Practice*. 1993;10(1):76-81.
21. Duffy J, Hirsch M, Ziebland S, McManus R. Methodological decisions influence the identification of potential core outcomes in studies related to pre-eclampsia: an analysis informing the development of recommendations for future core outcome set developers. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2019;126(12):1482-90.
22. Kirkham JJ, Davis K, Altman DG, Blazeby JM, Clarke M, Tunis S, et al. Core Outcome Set-STAndards for Development: The COS-STAD recommendations. *PLOS Medicine*. 2017;14(11):e1002447.
23. Webbe J, Brunton G, Ali S, Duffy JM, Modi N, Gale C. Developing, implementing and disseminating a core outcome set for neonatal medicine. *BMJ Paediatr Open*. 2017;1(1):e000048-e.
24. Whitehouse KC, Kim CR, Ganatra B, Duffy JMN, Blum J, Brahmi D, et al. Standardizing abortion research outcomes (STAR): a protocol for developing, disseminating and implementing a core outcome set for medical and surgical abortion. *Contraception*. 2017;95(5):437-41.
25. Khalil A, Perry H, Duffy J, Reed K, Baschat A, Deprest J, et al. Twin–Twin Transfusion Syndrome: study protocol for developing, disseminating, and implementing a core outcome set. *Trials*. 2017;18(1):325.
26. Khalil A, Duffy JMN, Perry H, Ganzevoort W, Reed K, Baschat AA, et al. Study protocol: developing, disseminating, and implementing a core outcome set for selective fetal growth restriction in monochorionic twin pregnancies. *Trials*. 2019;20(1):35.
27. Duffy J, McManus R. Influence of methodology upon the identification of potential core outcomes: recommendations for core outcome set developers are needed. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2016;123(10):1599-.
28. Diamond IR, Grant RC, Feldman BM, Pencharz PB, Ling SC, Moore AM, et al. Defining consensus: A systematic review recommends methodologic criteria for reporting of Delphi studies. *Journal of Clinical Epidemiology*. 2014;67(4):401-9.

29. Duffy J, Hirsch M, Pealing L, Showell M, Khan K, Ziebland S, et al. Inadequate safety reporting in pre-eclampsia trials: a systematic evaluation. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2018;125(7):795-803.
30. Duffy J, Bhattacharya S, Herman M, Mol B, Vail A, Wilkinson J, et al. Reducing research waste in benign gynaecology and fertility research. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2017;124(3):366-9.
31. Hirsch M, Duffy JMN, Kusznir JO, Davis CJ, Plana MN, Khan KS, et al. Variation in outcome reporting in endometriosis trials: a systematic review. *American Journal of Obstetrics and Gynecology*. 2016;214(4):452-64.
32. Perry H, Duffy JMN, Umadia O, Khalil A, Syndrome tICtHOtTTT. Outcome reporting across randomized trials and observational studies evaluating treatments for twin–twin transfusion syndrome: systematic review. *Ultrasound in Obstetrics & Gynecology*. 2018;52(5):577-85.
33. Webbe JWH, Ali S, Sakonidou S, Webbe T, Duffy JMN, Brunton G, et al. Inconsistent outcome reporting in large neonatal trials: a systematic review. *Archives of Disease in Childhood - Fetal and Neonatal Edition*. 2020;105(1):69-75.
34. Chan A, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. *BMJ*. 2013;346:e7586.
35. Graham L, Illingworth B, Showell M, Vercoe M, Crosbie E, Gingel L, et al. Research priority setting in women's health: a systematic review. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2020;127(6):694-700.
36. Townsend R, Duffy JMN, Khalil A. Increasing value and reducing research waste in obstetrics: towards woman-centered research. *Ultrasound in Obstetrics & Gynecology*. 2020;55(2):151-6.
37. Lam JR, Liu B, Bhate R, Fenwick N, Reed K, Duffy JMN, et al. Research priorities for the future health of multiples and their families: The Global Twins and Multiples Priority Setting Partnership. *Ultrasound in Obstetrics & Gynecology*. 2019;54(6):715-21.
38. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhalra N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. *The Lancet*. 2010;376(9753):1670-81.
39. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. Evidence-based guideline for the management of high blood pressure in adults. *JAMA: The Journal of the American Medical Association*. 2014;311(5):507-20.
40. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. ESH/ESC guidelines for the management of arterial hypertension: The task force for the management of

arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology. *Journal of Hypertension*. 2013;31(7):1281-357.

41. Duffy JMN, Hirsch M, Gale C, Pealing L, Kawsar A, Showell M, et al. A systematic review of primary outcome and outcome measure reporting in randomized trials evaluating treatments for preeclampsia. *International Journal of Gynecology and Obstetrics*. 2017;139(3):262-7.
42. Karumanchi SA, Granger JP. Preeclampsia and pregnancy-related hypertensive disorders. *Hypertension*. 2016;67(2):238-42.
43. Duffy JMN, Cairns AE, Magee L, von Dadelszen P, van 't Hooft J, Gale C, et al. Standardising definitions for the pre-eclampsia core outcome set: A consensus development study. *Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health*. Submitted for publication (29 Apr 2020).
44. Jansen L, Koot M, van't Hooft J, Dean C, Duffy J, Ganzevoort W, et al. A core outcome set for hyperemesis gravidarum research: an international consensus study. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2020; DOI: 10.1111/1471-0528.16172.
45. Duffy J, Hirsch M, Vercoe M, Abbott J, Barker C, Collura B, et al. A core outcome set for future endometriosis research: an international consensus development study. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2020; DOI: 10.1111/1471-0528.16157.
46. van 't Hooft J, Duffy JMN, Daly M, Williamson PR, Meher S, Thom E, et al. A Core Outcome Set for Evaluation of Interventions to Prevent Preterm Birth. *Obstetrics & Gynecology*. 2016;127(1):49-58.
47. Webbe JWH, Duffy JMN, Afonso E, Al-Muzaffar I, Brunton G, Greenough A, et al. Core outcomes in neonatology: development of a core outcome set for neonatal research. *Archives of Disease in Childhood*. 2019; DOI: 10.1136/archdischild-2019-317501.
48. Perry H, Duffy JMN, Reed K, Baschat A, Deprest J, Hecher K, et al. Core outcome set for research studies evaluating treatments for twin-twin transfusion syndrome. *Ultrasound in Obstetrics & Gynecology*. 2019;54(2):255-61.
49. Townsend R, Duffy JMN, Sileo F, Perry H, Ganzevoort W, Reed K, et al. Core outcome set for studies investigating management of selective fetal growth restriction in twins. *Ultrasound in Obstetrics & Gynecology*. Accepted for publication.
50. Duffy JMN, Bhattacharya S, Curtis C, Evers JLH, Farquharson RG, Franik S, et al. A protocol developing, disseminating and implementing a core outcome set for infertility. *Human Reproduction Open*. 2018;2018(3).

Table 1 Participant characteristics

	Delphi survey			Consensus development meeting n=16
	Round 1 n=432	Round 2 n=310	Round 3 n=273	
Stakeholder group (n, %)				
Patients	110, 25%	72, 23%	62, 23%	4, 25%
Healthcare professionals	281, 65%	201, 65%	181, 66%	11, 69%
Anesthetists	39, 9%	30, 10%	28, 10%	2, 13%
General practitioners	42, 10%	34, 11%	31, 11%	2, 13%
Midwives	35, 8%	30, 10%	27, 10%	3, 19%
Neonatologists or pediatricians	24, 6%	17, 5%	15, 5%	1, 6%
Obstetricians	113, 26%	72, 23%	65, 24%	2, 13%
Physicians	28, 6%	18, 6%	15, 5%	1, 6%
Researchers	41, 9%	37, 12%	30, 11%	2, 13%
Gender (n, %)				
Male	154, 36%	114, 37%	101, 37%	7, 44%
Female	277, 64%	195, 63%	171, 63%	10, 56%
Prefer not to say	1, <1%	1, <1%	1, <1%	
Age (years), (n, %)				
20 to 29	16, 3%	10, 3%	9, 3%	1, 6%
30 to 39	159, 37%	111, 36%	103, 38%	6, 38%
40 to 49	113, 26%	79, 25%	74, 27%	4, 25%
50 to 59	84, 19%	63, 20%	60, 11%	4, 25%
60 to 69	54, 13%	41, 13%	22, 8%	1, 6%
Over 70	4, <1%	4, 1%	4, 1%	1, 6%
Prefer not to say	2, <1%	2, <1%	1, <1%	0, 0%
Geographical location, (n, %)				
Africa	20, 5%	17, 5%	16, 6%	0, 0%
Asia	26, 6%	14, 5%	13, 5%	0, 0%
Australia	35, 8%	28, 9%	23, 8%	0, 0%
Europe	237, 55%	175, 56%	159, 58%	16, 100%
Middle East	7, 2%	4, 13%	4, 1%	0, 0%
North America	82, 19%	58, 19%	47, 17%	0, 0%
South America	23, 5%	13, 4%	11, 4%	0, 0%
Prefer not to say	2, <1%	1, <1%	0, 0%	0, 0%

Table 2 Core outcome set for preeclampsia

Maternal core outcomes

1. Maternal mortality
2. Eclampsia
3. Stroke
4. Cortical blindness
5. Retinal detachment
6. Pulmonary oedema
7. Acute kidney injury
8. Liver capsule haematoma or rupture
9. Placental abruption
10. Postpartum haemorrhage
11. Raised liver enzymes
12. Low platelets
13. Admission to intensive care unit required
14. Intubation and mechanical ventilation (not for childbirth)

Offspring outcomes

1. Stillbirth
2. Gestational age at delivery
3. Birth weight
4. Small-for-gestational-age
5. Neonatal mortality
6. Neonatal seizures
7. Admission to neonatal unit required
8. Respiratory support




Figure 1 Flow of participants and outcomes.